| Approximately 26% of controlled trial patients receiving glatiramer
acetate experienced what was described as transient chest pain.
Some of these episodes occurred immediately post-injection (approx
10%), however many did not. The significance of this remains unexplored.
Post marketing event reporting has indicated hypertension as a frequently
reported (at least 1/100) event for those on Copaxone ®.
Any causal relationship, if any, remains unknown.
|
